Celgene has new phase III data that could add yet another string to blockbuster Revlimid’s bow – as a treatment for patients with non-Hodgkin’s lymphoma who have relapsed or failed to respond to front-line therapy.
The AUGMENT trial paired Revlimid (lenalidomide) with Roche’s established lymphoma therapy Rituxan (rituximab) in patient with two types of NHL – follicular lymphoma (FL) and marginal zone lymphoma (MZL) – and showed a significant increase in progression-free survival (PFS) compared to Rituxan plus placebo.
There was also a trend towards an improvement in overall survival with Revlimid/Rituxan (known as R2), although the trial still has a while to run and that may reach statistical significance when the data matures.
Celgene is planning to file for approval of Revlimid in the new indication early next year, adding to its current uses in multiple myeloma, mantle cell lymphoma, and anaemia associated with myelodysplastic syndromes from which it generated sales of $8.19bn last year.
Read more: http://www.pmlive.com/pharma_news/celgenes_revlimid_gets_a_win_in_late-stage_lymphoma_1245500